Alligator Bioscience

About:

Alligator Bioscience develops antibody-based immunotherapies for the treatment of cancer by using its protein optimization technology FIND®.

Website: https://alligatorbioscience.se/en/

Top Investors: Home Capital AS, Malmsten Invest

Description:

Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for immunotherapy of cancer. Alligator discovers and develops drug development candidates up to phase IIa clinical studies. Alligator’s pipeline currently counts three immune-modulating projects, ADC-1013, ADC-1015, and ADC-1016. Alligator uses its proprietary technology platforms: ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a powerful in vitro based antibody optimization technology, in growing our pipeline.

Total Funding Amount:

51M SEK

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Lund, Skane Lan, Sweden

Founded Date:

2000-01-01

Contact Email:

info(AT)alligatorbioscience.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2007-05-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai